ProGen. Co., Ltd.
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus (NCT07677891) | ProGen. Co., Ltd. | 2026-10-01 |
| Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus (NCT07187856) | ProGen. Co., Ltd. | 2026-01-01 |
| Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes (NCT06712615) | ProGen. Co., Ltd. | 2024-12-05 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. (NCT06309667) | ProGen. Co., Ltd. | 2024-03-04 |
Track ProGen. Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.